StockData
Structure Therapeutics Inc. logo

Structure Therapeutics Inc. (GPCR) stock

GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$17.36−0.81 (-4.46%)

Close on Nov 18, 2026Market cap $1.24BP/E –Yield –

Structure Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Structure Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$257.81M. For fiscal 2025 it was -$176.56M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$176.56M–
FY2024Dec 31, 2024-$158.23M–
FY2023Dec 31, 2023-$102.78M–
FY2022Dec 31, 2022-$52.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$118.63M–
Q1 FY2026Mar 31, 2026-$89.38M–
Q4 FY2025Dec 31, 2025$23.99M–
Q3 FY2025Sep 30, 2025-$73.79M–
Q2 FY2025Jun 30, 2025-$70.45M–
Q1 FY2025Mar 31, 2025-$56.31M–
Q4 FY2024Dec 31, 2024-$47.06M–
Q3 FY2024Sep 30, 2024-$45.84M–
Q2 FY2024Jun 30, 2024-$33.32M–
Q1 FY2024Mar 31, 2024-$32.02M–
Q4 FY2023Dec 31, 2023-$30.99M–
Q3 FY2023Sep 30, 2023-$26.15M–
Q2 FY2023Jun 30, 2023-$25.99M–
Q1 FY2023Mar 31, 2023-$19.65M–
Q4 FY2022Dec 31, 2022-$12.96M–
Q3 FY2022Sep 30, 2022-$12.69M–
Q2 FY2022Jun 30, 2022-$13.96M–
Q1 FY2022Mar 31, 2022-$12.95M–

More Structure Therapeutics figures

See a number that looks wrong?